West Pharmaceutical Services, Inc. (WST) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1162760,
    "name": "West Pharmaceutical Services, Inc.",
    "stock_name": "West Pharmaceutical Services, Inc.",
    "full_name": "West Pharmaceutical Services, Inc.",
    "name_url": "stocks-analysis/west-pharmaceutical-services-inc",
    "exchange": 207,
    "exchangecode": "NYS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "281.77",
    "chg": -2.54,
    "chgp": "-0.89%",
    "dir": -1,
    "prev_price": "284.31",
    "mcapval": "18,507.12",
    "mcap": "Mid Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2325,
    "indexname": "S&P 500",
    "isin": "US9553061055",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "489.95 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/west-pharmaceutical-services-inc-1162760-207&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is West Pharmaceutical Services, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-west-pharmaceutical-services-inc-overvalued-or-undervalued-3637639",
        "imagepath": "",
        "date": "2025-10-21 12:06:15",
        "description": "As of 17 October 2025, the valuation grade for West Pharmaceutical Services, Inc. moved from very expensive to expensive, indicating a shift in perception regarding its valuation. The company appears to be overvalued, with a P/E ratio of 33, a Price to Book Value of 6.12, and an EV to EBITDA of 21.43, all of which are higher than many of its peers. For instance, Edwards Lifesciences Corp. has a P/E of 31.17 and an EV to EBITDA of 26.51, while Agilent Technologies, Inc. shows a more favorable P/E of 27.42 and an EV to EBITDA of 20.75.\n\nDespite recent short-term performance, where West Pharmaceutical outperformed the S&P 500 with a 1-week return of 3.37% compared to 1.70%, the longer-term outlook is concerning, with a year-to-date return of -17.39% versus the S&P 500's 13.30%. This trend suggests that while the stock may have some short-term momentum, its overall valuation metrics indicate it is not justified..."
      },
      {
        "title": "West Pharmaceutical Services, Inc. Experiences Revision in Its Stock Evaluation Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/west-pharmaceutical-services-valuation-grade-downgraded-from-very-expensive-to-expensive-3641014",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/WestPharmaceuti_valuationdot_3641014.png",
        "date": "2025-10-20 17:09:02",
        "description": "West Pharmaceutical Services, Inc. has adjusted its valuation metrics, with a P/E ratio of 33 and a price-to-book value of 6.12. The company has shown mixed performance, with recent stock returns outperforming the S&P 500, but a year-to-date decline contrasts with broader market gains."
      },
      {
        "title": "Is West Pharmaceutical Services, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-west-pharmaceutical-services-inc-overvalued-or-undervalued-3634509",
        "imagepath": "",
        "date": "2025-10-20 12:23:42",
        "description": "As of 17 October 2025, the valuation grade for West Pharmaceutical Services, Inc. has moved from very expensive to expensive, indicating a shift towards a less favorable valuation outlook. The company appears to be overvalued based on its current metrics, with a P/E ratio of 33, a Price to Book Value of 6.12, and an EV to EBITDA of 21.43. In comparison, peers such as Edwards Lifesciences Corp. have a P/E of 31.17 and Agilent Technologies, Inc. shows a more attractive P/E of 27.42, suggesting that West Pharmaceutical's valuation is not justified relative to its industry counterparts.\n\nWhile West Pharmaceutical has outperformed the S&P 500 over the past week and month, with returns of 3.37% and 5.44% respectively, it has significantly lagged over longer periods, with a year-to-date return of -17.39% compared to the S&P 500's 13.30%. This disparity reinforces the notion that the stock may be overvalued given i..."
      },
      {
        "title": "Is West Pharmaceutical Services, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-west-pharmaceutical-services-inc-overvalued-or-undervalued-3632047",
        "imagepath": "",
        "date": "2025-10-19 12:01:14",
        "description": "As of 17 October 2025, the valuation grade for West Pharmaceutical Services, Inc. has moved from very expensive to expensive, indicating a shift towards a less favorable assessment. The company appears to be overvalued based on its current metrics, with a P/E ratio of 33, a Price to Book Value of 6.12, and an EV to EBITDA of 21.43. In comparison to its peers, West Pharmaceutical's P/E ratio is notably higher than that of Agilent Technologies, Inc. at 27.42, which is considered fairly valued, and even exceeds Edwards Lifesciences Corp. at 31.17.\n\nDespite a recent positive stock performance with a 1-week return of 3.37% compared to the S&P 500's 1.70%, the longer-term outlook is concerning, as the company has experienced a year-to-date decline of 17.39% against the S&P 500's gain of 13.30%. This trend reinforces the notion that West Pharmaceutical is currently overvalued relative to its peers and market perfo..."
      },
      {
        "title": "West Pharmaceutical Services, Inc. Experiences Revision in Its Stock Evaluation Amid Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/west-pharmaceutical-services-valuation-grade-changes-from-fair-to-expensive-amid-price-decline-3617481",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/WestPharmaceuti_valuationdot_3617481.png",
        "date": "2025-10-13 15:56:01",
        "description": "West Pharmaceutical Services, Inc. has adjusted its valuation, reflecting changes in financial metrics within the Pharmaceuticals & Biotechnology industry. The company exhibits a P/E ratio of 33, a price-to-book value of 6.12, and strong returns on capital and equity, highlighting its competitive position among peers."
      },
      {
        "title": "Is West Pharmaceutical Services, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-west-pharmaceutical-services-inc-overvalued-or-undervalued-3612679",
        "imagepath": "",
        "date": "2025-10-12 11:08:25",
        "description": "As of 10 October 2025, the valuation grade for West Pharmaceutical Services, Inc. has moved from fair to expensive, indicating that the stock is overvalued. The company's P/E ratio stands at 33, which is higher than the peer average of 35.84 for similar companies, while its EV to EBITDA ratio is 21.43, also above the industry average. Additionally, the Price to Book Value ratio is 6.12, suggesting a premium valuation compared to its book value.\n\nIn comparison to its peers, Edwards Lifesciences Corp. has a P/E of 31.17, and Agilent Technologies, Inc. has a P/E of 27.42, both indicating that West Pharmaceutical is trading at a higher valuation. Over the past year, the stock has returned -9.76%, significantly underperforming the S&P 500, which returned 13.36%, reinforcing the notion that the stock may be overvalued in the current market...."
      },
      {
        "title": "West Pharmaceutical Services, Inc. Experiences Revision in Stock Evaluation Amid Market Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/west-pharmaceutical-services-inc-technical-trend-shifts-from-mildly-bearish-to-bullish-amid-stock-price-fluctuations-3601245",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/WestPharmaceuti_technicaldot_3601245.png",
        "date": "2025-10-07 20:31:54",
        "description": "West Pharmaceutical Services, Inc. has recently seen a revision in its evaluation, reflecting changes in technical indicators. The stock has shown significant volatility over the past year, with a notable performance disparity compared to the S&P 500, highlighting the challenges the company faces in the competitive Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Is West Pharmaceutical Services, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-west-pharmaceutical-services-inc-technically-bullish-or-bearish-3599022",
        "imagepath": "",
        "date": "2025-10-07 12:16:22",
        "description": "As of 3 October 2025, the technical trend for West Pharmaceutical Services, Inc. has changed from mildly bearish to bullish. The weekly MACD is bullish, and the monthly RSI is also bullish, indicating positive momentum. Daily moving averages are bullish, supporting the upward trend. However, the monthly KST is bearish, and the OBV shows a mildly bearish trend on the weekly timeframe, which suggests some caution. \n\nIn terms of performance, the stock has outperformed the S&P 500 over the past week and month, returning 2.98% and 6.92% respectively, while the S&P 500 returned 1.09% and 4.15%. However, the year-to-date and one-year returns are negative at -18.16% and -9.59%, significantly lagging behind the S&P 500's positive returns of 14.18% and 17.82%. Overall, the current stance is bullish, but with mixed signals that indicate a need for careful monitoring...."
      },
      {
        "title": "West Pharmaceutical Services Forms Golden Cross, Signaling Bullish Breakout Ahead",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/west-pharmaceutical-services-forms-golden-cross-signaling-bullish-breakout-ahead-3595293",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/WestPharmaceuti_goldencross_3595293.png",
        "date": "2025-10-06 15:29:55",
        "description": "West Pharmaceutical Services, Inc. has recently achieved a Golden Cross, indicating a potential shift in investor sentiment. The stock has shown strong short-term performance, outpacing the S&P 500, despite a challenging year-to-date. Bullish indicators suggest possible recovery opportunities in the competitive pharmaceuticals sector."
      }
    ],
    "total": 17,
    "sid": "1162760",
    "stock_news_url": "https://www.marketsmojo.com/news/west-pharmaceutical-services-inc-1162760"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is West Pharmaceutical Services, Inc. overvalued or undervalued?

2025-10-21 12:06:15

As of 17 October 2025, the valuation grade for West Pharmaceutical Services, Inc. moved from very expensive to expensive, indicating a shift in perception regarding its valuation. The company appears to be overvalued, with a P/E ratio of 33, a Price to Book Value of 6.12, and an EV to EBITDA of 21.43, all of which are higher than many of its peers. For instance, Edwards Lifesciences Corp. has a P/E of 31.17 and an EV to EBITDA of 26.51, while Agilent Technologies, Inc. shows a more favorable P/E of 27.42 and an EV to EBITDA of 20.75. Despite recent short-term performance, where West Pharmaceutical outperformed the S&P 500 with a 1-week return of 3.37% compared to 1.70%, the longer-term outlook is concerning, with a year-to-date return of -17.39% versus the S&P 500's 13.30%. This trend suggests that while the stock may have some short-term momentum, its overall valuation metrics indicate it is not justified...

West Pharmaceutical Services, Inc. Experiences Revision in Its Stock Evaluation Metrics

2025-10-20 17:09:02

West Pharmaceutical Services, Inc. has adjusted its valuation metrics, with a P/E ratio of 33 and a price-to-book value of 6.12. The company has shown mixed performance, with recent stock returns outperforming the S&P 500, but a year-to-date decline contrasts with broader market gains.

Is West Pharmaceutical Services, Inc. overvalued or undervalued?

2025-10-20 12:23:42

As of 17 October 2025, the valuation grade for West Pharmaceutical Services, Inc. has moved from very expensive to expensive, indicating a shift towards a less favorable valuation outlook. The company appears to be overvalued based on its current metrics, with a P/E ratio of 33, a Price to Book Value of 6.12, and an EV to EBITDA of 21.43. In comparison, peers such as Edwards Lifesciences Corp. have a P/E of 31.17 and Agilent Technologies, Inc. shows a more attractive P/E of 27.42, suggesting that West Pharmaceutical's valuation is not justified relative to its industry counterparts. While West Pharmaceutical has outperformed the S&P 500 over the past week and month, with returns of 3.37% and 5.44% respectively, it has significantly lagged over longer periods, with a year-to-date return of -17.39% compared to the S&P 500's 13.30%. This disparity reinforces the notion that the stock may be overvalued given i...

Is West Pharmaceutical Services, Inc. overvalued or undervalued?

2025-10-19 12:01:14

As of 17 October 2025, the valuation grade for West Pharmaceutical Services, Inc. has moved from very expensive to expensive, indicating a shift towards a less favorable assessment. The company appears to be overvalued based on its current metrics, with a P/E ratio of 33, a Price to Book Value of 6.12, and an EV to EBITDA of 21.43. In comparison to its peers, West Pharmaceutical's P/E ratio is notably higher than that of Agilent Technologies, Inc. at 27.42, which is considered fairly valued, and even exceeds Edwards Lifesciences Corp. at 31.17. Despite a recent positive stock performance with a 1-week return of 3.37% compared to the S&P 500's 1.70%, the longer-term outlook is concerning, as the company has experienced a year-to-date decline of 17.39% against the S&P 500's gain of 13.30%. This trend reinforces the notion that West Pharmaceutical is currently overvalued relative to its peers and market perfo...

West Pharmaceutical Services, Inc. Experiences Revision in Its Stock Evaluation Amid Market Dynamics

2025-10-13 15:56:01

West Pharmaceutical Services, Inc. has adjusted its valuation, reflecting changes in financial metrics within the Pharmaceuticals & Biotechnology industry. The company exhibits a P/E ratio of 33, a price-to-book value of 6.12, and strong returns on capital and equity, highlighting its competitive position among peers.

Is West Pharmaceutical Services, Inc. overvalued or undervalued?

2025-10-12 11:08:25

As of 10 October 2025, the valuation grade for West Pharmaceutical Services, Inc. has moved from fair to expensive, indicating that the stock is overvalued. The company's P/E ratio stands at 33, which is higher than the peer average of 35.84 for similar companies, while its EV to EBITDA ratio is 21.43, also above the industry average. Additionally, the Price to Book Value ratio is 6.12, suggesting a premium valuation compared to its book value. In comparison to its peers, Edwards Lifesciences Corp. has a P/E of 31.17, and Agilent Technologies, Inc. has a P/E of 27.42, both indicating that West Pharmaceutical is trading at a higher valuation. Over the past year, the stock has returned -9.76%, significantly underperforming the S&P 500, which returned 13.36%, reinforcing the notion that the stock may be overvalued in the current market....

West Pharmaceutical Services, Inc. Experiences Revision in Stock Evaluation Amid Market Volatility

2025-10-07 20:31:54

West Pharmaceutical Services, Inc. has recently seen a revision in its evaluation, reflecting changes in technical indicators. The stock has shown significant volatility over the past year, with a notable performance disparity compared to the S&P 500, highlighting the challenges the company faces in the competitive Pharmaceuticals & Biotechnology sector.

Is West Pharmaceutical Services, Inc. technically bullish or bearish?

2025-10-07 12:16:22

As of 3 October 2025, the technical trend for West Pharmaceutical Services, Inc. has changed from mildly bearish to bullish. The weekly MACD is bullish, and the monthly RSI is also bullish, indicating positive momentum. Daily moving averages are bullish, supporting the upward trend. However, the monthly KST is bearish, and the OBV shows a mildly bearish trend on the weekly timeframe, which suggests some caution. In terms of performance, the stock has outperformed the S&P 500 over the past week and month, returning 2.98% and 6.92% respectively, while the S&P 500 returned 1.09% and 4.15%. However, the year-to-date and one-year returns are negative at -18.16% and -9.59%, significantly lagging behind the S&P 500's positive returns of 14.18% and 17.82%. Overall, the current stance is bullish, but with mixed signals that indicate a need for careful monitoring....

West Pharmaceutical Services Forms Golden Cross, Signaling Bullish Breakout Ahead

2025-10-06 15:29:55

West Pharmaceutical Services, Inc. has recently achieved a Golden Cross, indicating a potential shift in investor sentiment. The stock has shown strong short-term performance, outpacing the S&P 500, despite a challenging year-to-date. Bullish indicators suggest possible recovery opportunities in the competitive pharmaceuticals sector.

View All News